H.R. 2821
FDA Modernization Act 3.0
Sponsor: Earl L. "Buddy" Carter
41 cosponsors
- Shri Thanedar
- Christopher H. Smith
- Claudia Tenney
- Randy K. Weber, Sr.
- Mark Pocan
- Jason Crow
- Thomas H. Kean, Jr.
- Diana Harshbarger
- Nanette Diaz Barragán
- Rosa L. DeLauro
- Troy A. Carter
- Vern Buchanan
- Eleanor Holmes Norton
- Maria Elvira Salazar
- Eugene Simon Vindman
- Joe Neguse
- Nicholas A. Langworthy
- Jay Obernolte
- Lloyd Doggett
- David G. Valadao
- Josh Harder
- Lois Frankel
- Julie Johnson
- Raja Krishnamoorthi
- Gus M. Bilirakis
- Scott Fitzgerald
- Brian K. Fitzpatrick
- Dan Crenshaw
- Jerrold Nadler
- Mike Carey
- Nicole Malliotakis
- Laurel M. Lee
- Josh Gottheimer
- Michael Lawler
- Young Kim
- Ken Calvert
- Ted Lieu
- Daniel S. Goldman
- Darren Soto
- Hillary J. Scholten
- Judy Chu
Official summary
Written by the Congressional Research Service.
FDA Modernization Act 3.0
This bill requires the Food and Drug Administration (FDA) to publish an interim final rule implementing a provision of the Consolidated Appropriations Act of 2023 that authorized the use of certain alternatives to animal testing to support investigational use of a new drug.
The rule must replace references to animal tests, data, studies, models, and research with references to nonclinical tests, data, studies, models, and research throughout the FDA’s regulations governing investigational new drug applications.
The rule must be published within one year of the bill’s enactment, and must take immediate effect as an interim final rule.